Literature DB >> 6702493

Treatment of digital vasospastic disease with the calcium-entry blocker nifedipine.

H Nilsson, T Jonasson, I Ringqvist.   

Abstract

Eight patients with vasospastic disease of the digital arteries were treated with the calcium-entry blocker nifedipine (capsules), 10 mg t.i.d. and 20 mg t.i.d. The degree of cold-induced digital vasospasm after local cooling of the finger to 15 and 10 degrees C, measured by strain-gauge technique, was significantly decreased by nifedipine. The degree of reduction was dose-dependent. All patients improved symptomatically. The side-effects of the drug were minor but became more prominent when the dose was increased. We conclude that nifedipine is a useful agent in the treatment of digital vasospastic disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6702493     DOI: 10.1111/j.0954-6820.1984.tb04983.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  5 in total

Review 1.  Use of nifedipine in hypertension and Raynaud's phenomenon.

Authors:  W Kiowski; P Erne; F R Bühler
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study.

Authors:  J Leppert; T Jonasson; H Nilsson; I Ringqvist
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

4.  Clinical and rheological effects of nifedipine in Raynaud's phenomenon.

Authors:  D G Waller; V F Challenor; D A Francis; O S Roath
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

5.  Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.

Authors:  T Gjørup; O J Hartling; H Kelbaek; S L Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.